New drugs for NASH

Non‐alcoholic steatohepatitis (NASH) is a result of inflammation and hepatocyte injury in the presence of hepatic steatosis which can progress to cirrhosis. NASH is the most rapidly growing aetiology for liver failure and indication for liver transplantation in the United States. Non‐alcoholic fatty...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2021-06, Vol.41 (S1), p.112-118
Main Authors: Albhaisi, Somaya A. M., Sanyal, Arun J.
Format: Article
Language:English
Subjects:
Body weight loss
Cirrhosis
clinical trials
Diabetes mellitus (non-insulin dependent)
Drug development
Drug therapy
Drugs
Dyslipidemia
Fatty liver
Fibrosis
Health services
Immunosuppressive agents
Inflammation
Liver
Liver diseases
Liver transplantation
Metabolic disorders
Metabolic syndrome
non‐alcoholic steatohepatitis
pharmacotherapy
Steatosis
Transplantation
Weight loss
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non‐alcoholic steatohepatitis (NASH) is a result of inflammation and hepatocyte injury in the presence of hepatic steatosis which can progress to cirrhosis. NASH is the most rapidly growing aetiology for liver failure and indication for liver transplantation in the United States. Non‐alcoholic fatty liver disease (NAFLD) is associated with obesity, type 2 diabetes, dyslipidaemia and metabolic syndrome. Because of the absence of approved pharmacotherapy, weight loss and lifestyle modifications remain the safest and most effective first‐line treatment. However, this may not be effective in patients with advanced fibrosis or cirrhosis and long‐term adherence is difficult to achieve. Therefore, effective drugs are urgently needed for the treatment of NASH. Drug development targeting pathological pathways in NASH have exploded in the past decade, with numerous new drugs under investigation. This review summarizes the results of pivotal finalized phase 2 studies and provides an outline of key active studies with trial data of drugs under development.
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.14844